SEATTLE, April 6 /PRNewswire/ -- Stratos Genomics Inc. today announced the addition of Heiner Dreismann, Ph.D., to its board of directors. The appointment increases board membership to seven.
While CEO of Roche Molecular Diagnostics, Dr. Dreismann led the development and commercialization of an expansive portfolio of PCR products, sustaining Roche's industry leadership in Molecular Diagnostics
Dr. Dreismann added, "I believe that Stratos Genomics' technology has the potential to radically transform the molecular diagnostics industry by, for the first time, performing individual whole genome sequencing at very low costs. It is a privilege to join this exciting and dynamic team, and I look forward to working closely with Al and the board members during the next stages of Stratos Genomics' growth."
In recent years, Dr. Dreismann has served as a director of several public and privately held diagnostic companies.
Stratos Genomics Inc. is a spin-out of Seattle-based Stratos Group LLC focused on the development of low-cost whole genome sequencing technology. Stratos Group is dedicated to the conversion of science and technology into commercial solutions for the advancement of mankind and the protection of the environment. Also under the Stratos Group umbrella is Stratos Product Development LLC. Stratos Product Development is a world leader in high tech product development services. For more information, visit www.stratos.com.
CONTACT: David Schull, Russo Partners, LLC, +1-619-528-2220,
David.Schull@RussoPartnersLLC.com; Ian Stone, Russo Partners, LLC,
Web site: http://www.stratos.com/